PLBD1-CREBL2 Fusion FISH Probe
The PLBD1-CREBL2 Fusion FISH Probe is used to confirm a fusion of the PLBD1 and CREBL2 genes. The fusion of the PLBD1 and CREBL2 genes has been associated with Bladder Urothelial Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| PLBD1-CREBL2-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-RERE | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-REOR | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-REGO | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-REGR | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-OROR | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-GORE | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-GROR | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| PLBD1-CREBL2-20-AQAQ | 20 (40 μL) | 200 μL |
|
CREBL2 Gene Summary
cAMP response element (CRE)-binding protein-like-2 (CREBL2) was identified in a search to find genes in a commonly deleted region on chromosome 12p13 flanked by ETV6 and CDKN1B genes, frequently associated with hematopoietic malignancies, as well as breast, non-small-cell lung and ovarian cancers. CREBL2 shares a 41% identity with CRE-binding protein (CREB) over a 48-base long region which encodes the bZip domain of CREB. The bZip domain consists of about 30 amino acids rich in basic residues involved in DNA binding, followed by a leucine zipper motif involved in protein dimerization. This suggests that CREBL2 encodes a protein with DNA binding capabilities. The occurance of CREBL2 deletion in malignancy suggests that CREBL2 may act as a tumor suppressor gene. [provided by RefSeq, Jul 2008]
Gene Name: CAMP Responsive Element Binding Protein Like 2
Chromosome: CHR12: 12764830 -12798041
Locus: 12p13.1
PLBD1 Gene Summary
The Phospholipase B Domain Containing 1 (PLBD1) gene is located on chr12 :14656596-14720791 at 12p13.1.
Gene Name: Phospholipase B Domain Containing 1
Chromosome: CHR12: 14656596 -14720791
Locus: 12p13.1
Gene Diseases
The PLBD1 CREBL2 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Bladder Urothelial Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|